Novo Nordisk remains a Strong Buy, supported by robust volume growth in GLP-1 products despite recent earnings misses and price compression. NVO's oral Wegovy launch exceeded Street expectations, with superior unit economics and a global rollout driving future volume and margin expansion. Upcoming catalysts include Medicare coverage for Wegovy, international launches, and pipeline progress, notably CagriSema and the REIMAGINE program.